Literature DB >> 17045242

Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells.

Cristina Cigana1, Elena Nicolis, Matteo Pasetto, Baroukh Maurice Assael, Paola Melotti.   

Abstract

We aimed at identifying molecular mechanisms for anti-inflammatory effects of azithromycin (AZM) suggested by clinical evidences. IL-8 expression and DNA binding activity of two key pro-inflammatory transcription factors (TF), NF-kappaB and AP-1, were investigated in cystic fibrosis (CF) and isogenic non-CF airway epithelial cell lines. AZM reduced about 40% of IL-8 mRNA and protein expression (n=9, p=0.02, and n=4, p=0.00011) in CF cells reaching the levels of non-CF cells. In the presence of AZM we found about 50% and 70% reduction of NF-kappaB and AP-1 DNA binding, respectively (n=3, p=0.01, and n=3, p=0.0017), leading to levels of non-CF cells. The relevance of NF-kappaB and AP-1 in regulating IL-8 promoter transcriptional activity was demonstrated by gene reporter assays (n=4, p=8.54x10(-7), and n=4, p=6.45x10(-6)). Our data support the anti-inflammatory effects of AZM in CF cells, indicating inhibition of transcription of pro-inflammatory genes as possible mechanism, thus providing a rationale for the possible use of specific TF inhibitors for therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045242     DOI: 10.1016/j.bbrc.2006.09.132

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  37 in total

1.  The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.

Authors:  Andrew J McDermott; Kathryn E Higdon; Ryan Muraglia; John R Erb-Downward; Nicole R Falkowski; Roderick A McDonald; Vincent B Young; Gary B Huffnagle
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

2.  Suppressive effects of azithromycin on zymosan-induced production of proinflammatory mediators by human corneal epithelial cells.

Authors:  De-Quan Li; Nan Zhou; Lili Zhang; Ping Ma; Stephen C Pflugfelder
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

3.  Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.

Authors:  Felix Ratjen; Lisa Saiman; Nicole Mayer-Hamblett; Larry C Lands; Margaret Kloster; Valeria Thompson; Peggy Emmett; Bruce Marshall; Frank Accurso; Scott Sagel; Michael Anstead
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

Review 4.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

5.  Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells.

Authors:  Cristina Cigana; Baroukh Maurice Assael; Paola Melotti
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

6.  In-vitro evaluation of a ciprofloxacin and azithromycin sinus stent for Pseudomonas aeruginosa biofilms.

Authors:  Dong-Jin Lim; Daniel Skinner; John Mclemore; Nick Rivers; Jeffrey Brent Elder; Mark Allen; Connor Koch; John West; Shaoyan Zhang; Harrison M Thompson; Justin P McCormick; Jessica W Grayson; Do-Yeon Cho; Bradford A Woodworth
Journal:  Int Forum Allergy Rhinol       Date:  2019-11-06       Impact factor: 3.858

7.  Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration.

Authors:  Pin-Chuang Lai; Weiting Ho; Nidhi Jain; John D Walters
Journal:  J Periodontol       Date:  2011-03-21       Impact factor: 6.993

8.  Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice.

Authors:  Wan C Tsai; Marc B Hershenson; Ying Zhou; Umadevi Sajjan
Journal:  Inflamm Res       Date:  2009-03-07       Impact factor: 4.575

9.  Adult onset lung disease following transient disruption of fetal stretch-induced differentiation.

Authors:  Joseph J Hudak; Erin Killeen; Ashok Chandran; J Craig Cohen; Janet E Larson
Journal:  Respir Res       Date:  2009-05-06

10.  Pseudomonas aeruginosa exploits lipid A and muropeptides modification as a strategy to lower innate immunity during cystic fibrosis lung infection.

Authors:  Cristina Cigana; Laura Curcurù; Maria Rosaria Leone; Teresa Ieranò; Nicola Ivan Lorè; Irene Bianconi; Alba Silipo; Flora Cozzolino; Rosa Lanzetta; Antonio Molinaro; Maria Lina Bernardini; Alessandra Bragonzi
Journal:  PLoS One       Date:  2009-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.